Eton Pharmaceuticals, Inc.
ETON
$17.29
-$0.17-0.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.18M | 48.33M | 39.01M | 34.68M | 31.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.18M | 48.33M | 39.01M | 34.68M | 31.38M |
| Cost of Revenue | 22.41M | 20.06M | 15.60M | 14.11M | 12.72M |
| Gross Profit | 35.77M | 28.27M | 23.41M | 20.57M | 18.67M |
| SG&A Expenses | 30.45M | 26.35M | 22.34M | 20.61M | 19.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.37M | 50.18M | 41.19M | 39.90M | 37.66M |
| Operating Income | 815.00K | -1.85M | -2.18M | -5.22M | -6.28M |
| Income Before Tax | -4.03M | -4.50M | -3.81M | -5.31M | -6.39M |
| Income Tax Expenses | 101.00K | 89.00K | 15.00K | 175.00K | 301.00K |
| Earnings from Continuing Operations | -4.13 | -4.58 | -3.82 | -5.48 | -6.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.13M | -4.58M | -3.82M | -5.48M | -6.69M |
| EBIT | 815.00K | -1.85M | -2.18M | -5.22M | -6.28M |
| EBITDA | 3.40M | 3.00K | -1.11M | -4.17M | -5.31M |
| EPS Basic | -0.15 | -0.18 | -0.15 | -0.21 | -0.26 |
| Normalized Basic EPS | -0.06 | -0.10 | -0.08 | -0.13 | -0.16 |
| EPS Diluted | -0.17 | -0.19 | -0.16 | -0.22 | -0.26 |
| Normalized Diluted EPS | -0.06 | -0.10 | -0.08 | -0.13 | -0.16 |
| Average Basic Shares Outstanding | 105.82M | 104.70M | 103.58M | 103.18M | 103.00M |
| Average Diluted Shares Outstanding | 106.47M | 105.35M | 104.23M | 103.83M | 103.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |